unknown
Stage
1
Investors
About
CC Diagnostics develops a PCR-based reagent kit using novel biomarkers for accurate and early detection of cervical cancer, improving sensitivity and reducing diagnostic delays compared to traditional screening methods.
Explore CC Diagnostics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.